此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Swiss Pilot Screening Study for Unruptured Intracranial Aneurysms to Prevent Subarachnoid Hemorrhage in Smokers

2026年11月10日 更新者:Insel Gruppe AG, University Hospital Bern

Unruptured intracranial aneurysms (UIAs) are potentially life-threatening vascular lesions that may rupture and cause aneurysmal subarachnoid hemorrhage (SAH), a condition associated with substantial morbidity and mortality. The prevalence of UIAs in the general population is approximately 3.2%. Current guidelines recommend screening primarily for individuals with a strong family history of UIA/SAH or autosomal dominant polycystic kidney disease (ADPKD). However, these groups account for only a minority of patients with UIAs.

Smoking is a major modifiable risk factor for UIA formation and rupture. Preliminary studies suggest that UIA prevalence may be substantially higher among smokers than in the general population, but prospective data are limited, particularly in men.

This prospective screening study aims to determine the prevalence of UIAs in active and recent smokers aged 30-60 years with a smoking history of at least 10 pack-years. We hypothesize that UIA prevalence in this population is significantly higher than in the general population and may approach that of established high-risk groups.

Participants will undergo non-contrast 3T magnetic resonance angiography (time-of-flight sequence). Baseline demographic and clinical characteristics, smoking habits, nicotine dependence, and quality of life will be assessed using REDCap questionnaires. Imaging findings will be communicated to participants, and those with detected aneurysms or relevant incidental findings will be referred for standard clinical evaluation. At 30 (±14) days after MRI, smoking habits, nicotine dependence, quality of life, and consequences of screening will be reassessed. The study will also evaluate the clinical implications and costs of screening.

研究概览

详细说明

Unruptured intracranial aneurysms (UIA) are an asymptomatic but potentially life-threatening cardiovascular condition. Rupture leads to aneurysmal subarachnoid hemorrhage (SAH), which is associated with high morbidity and mortality and causes 25% of all cerebrovascular-related deaths. In Switzerland, approximately 275'000 people harbor an UIA. Screening with imaging for detection of UIA to occlude them preventively and thus reduce SAH incidence is recommended according to current guidelines only in patients with ≥2 family members with a history of UIA/SAH or who suffer from autosomal dominant polycystic kidney disease (ADPKD). In these two groups, considered to be at high risk of having UIA, the prevalence of UIA is estimated to be 10%, compared with an approximate prevalence of 3.2% in the general population. However, patients with a positive family history for ≥2 family members or ADPKD represent an absolute minority of all UIA patients.

In contrast, smoking is common in SAH patients and is the most substantial risk factor for SAH. Approximately 40% of patients presenting with SAH are active smokers, and 39% of smokers with UIA will experience SAH during their lifetime. There are few but interesting data on the prevalence of UIA in middle-aged women who are smokers, as the incidence of SAH is highest in this subgroup. A retrospective nested case-control study in 30 to 60-year-old women who underwent head MRI for various indications found an UIA prevalence of 19% in female smokers compared to a prevalence of 1.9% in non-smoking females. Further, a recent small screening study found an UIA prevalence of 12% (5 out of 43) in female smokers.

Switzerland has implemented several tobacco control measures over the past 25 years, and tobacco use declined moderately until 2007. Since then, smoking prevalence has stabilized but remains relevantly high at approximately one-quarter of the population. 27% of the Swiss population (15 years and older) are active smokers, and 22% are former smokers. Smoking 20 or more cigarettes a day is considered heavy smoking, is prevalent in 6% of the population and is more common in men (8% men, 4% women). Although previous studies screened women exclusively, smoking is the most critical risk factor for SAH in both sexes, and Swiss men are more frequently heavy smokers than women.

Smoking cessation leads to a decrease in SAH incidence and is, contrary to ADPKD and positive family history of SAH/UIA, a risk factor that can be targeted with lifestyle modifications to prevent future SAH. These data and the continuing relevant health burden caused by smoking challenge the current screening approach towards a risk factor-based UIA screening strategy targeting smoking patients. To investigate the value of such risk factor-based screening, more extensive data on UIA prevalence in smokers is needed, particularly in men, because they are missing.

We hypothesize that the prevalence of UIA in active smokers is relevantly higher than the average UIA-prevalence of 3.2% and comparable to other high-risk groups (≥2 family members with a history of SAH/UIA, ADPKD) in whom guidelines currently recommend screening. Further, we hypothesize that in a relevant proportion of UIAs that could potentially be detected by such screening, the risk of natural history is higher than the risk of treatment resulting in a recommendation to perform preventive aneurysm occlusion or to undergo lifestyle modifications and follow-up with imaging.

After obtaining the signed informed consent and inclusion in the study, demographics, risk factors for SAH / UIA, QoL (15-D questionnaire), and nicotine dependence, will be assessed in an online questionnaire and with help of an online survey tool (REDCap). The 3T-MRI examination will be scheduled as a next step, and the appointment will be communicated to the participant. The 3T-MRI exams will take place at the Translational Imaging Senter in Sitem-insel. As MRI machine we will use a 3 T scanner (MAGNETOM Prisma, Siemens Healthcare) with a standard head coil. The time for acquiring the necessary TOF-angiography sequence is approximately 5 minutes. After the examination, participants can go directly home and no further examinations will be performed at this appointment. Within seven days after the examination, participants will be contacted by the study team via telephone and findings of the examination will be communicated. If a UIA or an incidental finding is detected, the patients will be called to a consultation in the outpatient clinic outside of the study and will be managed based on the finding with standard care. 30 (±14) days after the MRI examination, QoL, changes in smoking habits, and nicotine dependence will again be collected via an online questionnaire and with help of an online survey tool (REDCap). Furthermore, planned or completed interventions and consequences of the screening findings will be collected, as well as costs of screening and potential interventions will be recorded.

The maximum duration of the study after the MRI examination is 30 (±14) days. Depending on the availability of MRI slots, the period between inclusion and MRI examination may vary but should not exceed 8 (±4) weeks.

研究类型

介入性

注册 (估计的)

200

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

    • Canton of Bern
      • Bern、Canton of Bern、瑞士、3010

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

30年 至 60年 (成人)

接受健康志愿者

是的

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Women and men
  • Age 30-60 years
  • Active cigarette smoking with a cumulative exposure ≥ 10 pack-years
  • Smoking cessation no longer than 6 months ago (<6 months

Exclusion Criteria:

  • Contraindications to undergo MRI
  • Patients with known UIA
  • History of subarachnoid hemorrhage
  • History of polycystic kidney disease, Ehlers-Danlos syndrome, Marfan's syndrome, fibromuscular dysplasia, Moya-Moya disease, or Loeys-Dietz syndrome, history of ≥2 family members with SAH/UIA
  • Pregnancy

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:诊断
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:screening for unruptured intracranial aneurysms

3T-MRI examination for Unruptured intracranial aneurysms

After obtaining the signed informed consent, demographics, risk factors for SAH / UIA, QoL (15-D questionnaire), and nicotine dependence, will be assessed in an online questionnaire. The 3T-MRI examination will be performed. The time for acquiring the necessary TOF-angiography sequence is approximately 5 minutes. Within seven days after the examination, participants will be contacted by the study team via telephone and findings of the examination will be communicated. If a UIA or an incidental finding is detected, the patients will be called to a consultation in the outpatient clinic outside of the study and will be managed based on the finding with standard care. 30 (±14) days after the MRI examination, QoL, changes in smoking habits, and nicotine dependence will again be collected via an online questionnaire. Furthermore, planned or completed interinterventions and consequences of the screening findings will be collected.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
percentage of Unruptured intracranial aneurysms detected by screening
大体时间:30 days after MRI

Diagnostic yield calculated as the percentage of UIAs detected by screening

30 days after MRI

次要结果测量

结果测量
措施说明
大体时间
Kind of interventions for detected Unruptured intracranial aneurysms (none, observation/lifestyle modifications, preventive occlusion)
大体时间:30 days after MRI

Interventions for detected Unruptured intracranial aneurysms (none, observation/lifestyle modifications, preventive occlusion)

30 days after MRI
Location of detected Unruptured intracranial aneurysms
大体时间:7 days after MRI
7 days after MRI
Morphology of detected Unruptured intracranial aneurysms
大体时间:7 days after MRI
7 days after MRI
Size of detected Unruptured intracranial aneurysms
大体时间:7 days after MRI
7 days after MRI
Prevalence of incidental findings
大体时间:7 days after MRI
7 days after MRI
Description of incidental MRI findings
大体时间:7 days after Baseline MRI
7 days after Baseline MRI
Health Related Quality of Life (HRQoL) 15D
大体时间:at Baseline and 30 days after Baseline MRI

15D is a generic, comprehensive, 15-dimensional, standardized, self-administered measure of health-related quality of life (HRQoL). It includes the following 15 dimensions: breathing, mental function, speech (communication), vision, mobility, usual activities, vitality, hearing, eating, elimination, sleeping, distress, discomfort and symptoms, sexual activity, and depression. The maximum score is 1 (no problems on any dimension) and the minimum score is 0. A change of 0.02-0.03 has been observed to be such that people can feel the difference.

at Baseline and 30 days after Baseline MRI
Effect of smoking dependency/smoking habits
大体时间:assessed before and after MRI
assessed before and after MRI
Costs of screening
大体时间:day 7 after MRI

Costs of screening compared to costs of SAH

day 7 after MRI
Costs of potential interventions
大体时间:day 7 after MRI

Costs of potential interventions (including incidental findings) compared to costs of SAH

day 7 after MRI
UIA detection rate with software
大体时间:day 7 after MRI
day 7 after MRI
Prevalence ouf detected UIAs stratified by sex
大体时间:day 7 after MRI
day 7 after MRI
Prevalence ouf detected UIAs stratified by pack-years
大体时间:day 7 after MRI
day 7 after MRI
Prevalence ouf detected UIAs stratified by age
大体时间:day 7 after MRI
day 7 after MRI

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Johannes Goldberg, MD、Inselspital Bern, Department of Neurosurgery

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2023年7月28日

初级完成 (估计的)

2027年7月31日

研究完成 (估计的)

2028年1月31日

研究注册日期

首次提交

2026年10月26日

首先提交符合 QC 标准的

2026年11月10日

首次发布 (实际的)

2026年11月16日

研究记录更新

最后更新发布 (实际的)

2026年11月16日

上次提交的符合 QC 标准的更新

2026年11月10日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅